International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial

Imagem de Miniatura
Arquivos
art_SANTOS_International_Variation_in_Outcomes_Among_People_with_Cardiovascular_2017.PDF (918.7 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
SHARMA, Abhinav
SUN, Jie-Lena
PIEPER, Karen
MCMURRAY, John J. V.
HOLMAN, Rury R.
LOPES, Renato D.
Citação
JOURNAL OF THE AMERICAN HEART ASSOCIATION, v.6, n.1, article ID e003892, 11p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background-Regional differences in risk of diabetes mellitus and cardiovascular outcomes in people with impaired glucose tolerance are poorly characterized. Our objective was to evaluate regional variation in risk of new-onset diabetes mellitus, cardiovascular outcomes, and treatment effects in participants from the NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) trial. Methods and Results-NAVIGATOR randomized people with impaired glucose tolerance and cardiovascular risk factors or with established cardiovascular disease to valsartan (or placebo) and to nateglinide (or placebo) with a median 5-year follow-up. Data from the 9306 participants were categorized by 5 regions: Asia (n= 552); Europe (n= 4909); Latin America (n= 1406); North America (n= 2146); and Australia, New Zealand, and South Africa (n= 293). Analyzed outcomes included new-onset diabetes mellitus; cardiovascular death; a composite cardiovascular outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke; and treatment effects of valsartan and nateglinide. Respective unadjusted 5-year risks for new-onset diabetes mellitus, cardiovascular death, and the composite cardiovascular outcome were 33%, 0.4%, and 4% for Asia; 34%, 2%, and 6% for Europe; 37%, 4%, and 8% for Latin America; 38%, 2%, and 6% for North America; and 32%, 4%, and 8% for Australia, New Zealand, and South Africa. After adjustment, compared with North America, European participants had a lower risk of new-onset diabetes mellitus (hazard ratio 0.86, 95% CI 0.78-0.94; P= 0.001), whereas Latin American participants had a higher risk of cardiovascular death (hazard ratio 2.68, 95% CI 1.82-3.96; P< 0.0001) and the composite cardiovascular outcome (hazard ratio 1.48, 95% CI 1.15-1.92; P= 0.003). No differential interactions between treatment and geographic location were identified. Conclusions-Major regional differences regarding the risk of new-onset diabetes mellitus and cardiovascular outcomes in NAVIGATOR participants were identified. These differences should be taken into account when planning global trials.
Palavras-chave
cardiovascular disease, diabetes mellitus, risk factor
URI
https://observatorio.fm.usp.br/handle/OPI/18979
Referências
  1. Boyle JP, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-29
  2. Califf RM, 2008, AM HEART J, V156, P623, DOI 10.1016/j.ahj.2008.05.017
  3. Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5
  4. Edelstein SL, 1997, DIABETES, V46, P701, DOI 10.2337/diabetes.46.4.701
  5. Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8
  6. Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301
  7. Heianza Y, 2011, LANCET, V378, P147, DOI 10.1016/S0140-6736(11)60472-8
  8. Holman RR, 2010, NEW ENGL J MED, V362, P1463, DOI 10.1056/NEJMoa1001122
  9. International Diabetes Federation, 2015, IDF DIABETES ATLAS, P1
  10. Knowler WC, 2002, NEW ENGL J MED, V346, P393
  11. Ligthart S, 2016, LANCET DIABETES ENDO, V4, P44, DOI 10.1016/S2213-8587(15)00362-9
  12. Lindstrom J, 2006, LANCET, V368, P1673, DOI 10.1016/S0140-6736(06)69701-8
  13. Lopez-Jaramillo Patricio, 2011, Ther Adv Cardiovasc Dis, V5, P119, DOI 10.1177/1753944711403189
  14. McMurray JJ, 2010, NEW ENGL J MED, V362, P1477, DOI 10.1056/NEJMoa1001121
  15. Mentz RJ, 2012, AM HEART J, V164, P303, DOI 10.1016/j.ahj.2012.06.006
  16. Nathan DM, 2007, DIABETES CARE, V30, P753, DOI 10.2337/dc07-9920
  17. Noble D, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d7163
  18. Preiss D, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001925
  19. Venkitachalam L, 2012, CIRCULATION, V125, P1858, DOI 10.1161/CIRCULATIONAHA.111.064378
  20. World Health Organization, 2016, GUID SCREEN CAR TREA, P1
  21. Woodward M, 2011, DIABETES CARE, V34, P2491, DOI 10.2337/dc11-0755
  22. Yeboah J, 2011, J AM COLL CARDIOL, V58, P140, DOI 10.1016/j.jacc.2011.03.025
  23. Yusuf S, 2014, NEW ENGL J MED, V371, P818, DOI 10.1056/NEJMoa1311890

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - ODS/03